DOCSLIB.ORG

Capecitabine-Induced Hand-Foot Syndrome Complicated by Pseudomonal Superinfection Resulting in Bacterial Sepsis and Death Case Report and Review of the Literature

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Capecitabine-Induced Hand-Foot Syndrome Complicated by Pseudomonal Superinfection Resulting in Bacterial Sepsis and Death Case Report and Review of the Literature OBSERVATION Capecitabine-Induced Hand-Foot Syndrome Complicated by Pseudomonal Superinfection Resulting in Bacterial Sepsis and Death Case Report and Review of the Literature Fridolin J. Hoesly, MD; Sarah G. Baker, MD; Nilanthi D. Gunawardane, MD; Jonathan A. Cotliar, MD Background: Hand-foot syndrome (HFS) is a rela- over both hands and feet, consistent with HFS. Pseudo- tively common dermatologic toxic reaction to certain monal superinfection leading to bacterial sepsis and death anticancer therapies. Although not life-threatening, this rapidly ensued. complication can reduce patient quality of life. Dose modi- fication of the inciting agent serves as the most effective Conclusions: Although HFS is widely regarded as a non– management of HFS, although a variety of anecdotal re- life-threatening toxic reaction to cancer treatment, our ports suggest that other agents may also be efficacious. case demonstrates that infectious complications of this We present the first reported case of fatal HFS (to our condition can prove fatal. Prevention, early recogni- knowledge) and provide a comprehensive review of this tion, and implementation of various management strat- condition. egies for HFS and its infectious complications are im- portant in optimizing patient quality of life and minimizing Observations: A 61-year-old woman with metastatic unfavorable outcomes. breast cancer who was undergoing treatment with ca- pecitabine developed erythema, fissuring, and erosions Arch Dermatol. 2011;147(12):1418-1423 AND-FOOT SYNDROME REPORT OF A CASE (HFS), also known as pal- moplantar erythrodyses- thesia or acral erythema, A 61-year-old woman with metastatic breast is a localized skin erup- cancer who had been treated with oral lapa- tion associated with the initiation of tinib (1250 mg/d) and capecitabine (1250 H 2 therapy with certain chemotherapeutic mg/m twice daily) over the previous 4 years agents.1,2 It is considered a subtype of toxic presented with a 3-week history of painful erythema of chemotherapy, a term that en- erosions and ulcerations of her hands and compasses a broad spectrum of antican- feet along with bilateral lower extremity cer medication–induced cutaneous reac- swelling. She denied any other symptoms, and her medical history was otherwise tions.3 The clinical presentation of HFS is unremarkable. Her other medications in- characterized by a prodrome of dysesthe- cluded fulvestrant and pamidronate. Dur- sia followed by the development of pain- ing the previous 3 years, she had experi- ful, symmetrical edema and erythema of enced intermittent flares of grades 1 and 2 the palms, digits, and soles that may evolve 4,5 HFS due to capecitabine use. Her symp- into blisters and erosions. Although HFS toms were successfully treated with fluoci- has the potential to substantially affect nonide cream, 0.05%, and ammonium lac- quality of life, it is not recognized as a life- tate cream, 12%, although she had not been 6 threatening condition and rarely leads to treating her skin with topical agents before hospitalization.7 We report a case of HFS her appointment. Physical examination re- that was complicated by pseudomonal su- vealed erythema and fissuring over both perinfection resulting in bacterial sepsis Author Affiliations: palms and circumferential erosions involv- Department of Dermatology, and death and provide a review of the HFS ing her right thumb and left middle finger Northwestern University literature focusing on the management of (Figure 1A). She had bilateral lower ex- Feinberg School of Medicine, this condition. To our knowledge, this is tremity edema as well as erythema and ero- Chicago, Illinois. the first reported case of fatal HFS. sions over both soles and the web spaces of ARCH DERMATOL/ VOL 147 (NO. 12), DEC 2011 WWW.ARCHDERMATOL.COM 1418 ©2011 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 A B Figure 1. Diffuse erythema and fissuring of the palms with focal erosions on the fingers (A) and the right foot (B). her feet (Figure 1B). A diagnosis of grade 3 HFS was made of a subungual abscess that formed after onycholysis; how- according to the National Cancer Institute (NCI) Com- ever, HFS was not identified as a contributing factor.10 mon Terminology Criteria for Adverse Events version 4.0, Our case demonstrates the life-threatening potential of and capecitabine therapy was discontinued. Treatment with HFS and highlights the importance of its prevention, mupirocin ointment, econazole cream, and oral ciprofloxa- prompt recognition, and appropriate management. cin was initiated because of a clinical suspicion of cutane- The NCI grading scale is commonly used to rate HFS ous superinfection and the patient’s history of Pseudomo- (categorized as palmar-plantar erythrodysesthesia syn- nas aeruginosa paronychia of her left great toe 7 months drome and described as redness, marked discomfort, earlier. Wound cultures obtained from both the hands and swelling, and tingling of the palms and/or soles) sever- the feet during the initial evaluation yielded pansensitive ity on a scale of 1 to 3 (Table 1).11 Almost 80% of pa- P aeruginosa. The patient was contacted to discuss the cul- tients with HFS present with NCI grade 1 toxicity.4 ture results, and at that time she reported the onset of mal- The most common causes of HFS include aise and scleral icterus. She was instructed to go to the emer- capecitabine, cytosine arabinoside (cytarabine), doxoru- gency department, and on arrival she was found to be in bicin, 5-fluorouracil, and the taxanes.3,4 Our patient septic shock, with acute kidney injury and hepatic dys- developed HFS as a result of capecitabine therapy, function, resulting in coagulopathy. Pseudomonal super- which causes this condition in 28% to 74% of treated infection of the patient’s HFS was considered the most likely patients.12 Capecitabine is a prodrug that is enzymati- source of sepsis, although the results of blood cultures re- cally converted to 5-fluorouracil within tumor cells. mained negative. Despite broad-spectrum intravenous an- The onset of HFS can range from within 24 hours to 10 tibiotic therapy and aggressive resuscitative measures, she months of the initiation of chemotherapy, with shorter died less than 24 hours later. time to onset and greater severity being associated with higher peak plasma levels and total cumulative COMMENT dose.2,4,12 Capecitabine-related HFS usually appears within the first 3 cycles of treatment13 and commonly It is well known that HFS can have a dramatic impact worsens in subsequent cycles,1 as occurred in this case. on quality of life and can necessitate dose modification Our patient was also taking lapatinib, a dual inhibitor of or discontinuation of cancer therapy; however, it is not epidermal growth factor receptor and human epidermal considered a dangerous condition in and of itself. There growth factor receptor 2; however, this drug is most have been a few reports of HFS leading to tissue necro- commonly associated with the development of skin sis and requiring amputation,8,9 but we report the first eruptions that are localized to the trunk.14 In one death (to our knowledge) due to complications of HFS. review, fewer than 1% of the 926 patients who were In a study evaluating weekly docetaxel plus ca- receiving lapatinib monotherapy developed HFS.14 Of pecitabine therapy for advanced non–small cell lung can- interest, multikinase inhibitors such as sorafenib and cer, there was 1 reported death due to sepsis as a result sunitinib also cause a similar cutaneous toxic reaction ARCH DERMATOL/ VOL 147 (NO. 12), DEC 2011 WWW.ARCHDERMATOL.COM 1419 ©2011 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 Table 1. National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 Grading of Hand-Foot Syndromea Grade Adverse Event Term 123 Palmar-plantar erythrodysesthesia Minimal skin changes (erythema, Skin changes (peeling, blisters, Severe skin changes (peeling, syndrome (hand-foot syndrome) edema, or hyperkeratosis) bleeding, edema, or blisters, bleeding, edema, or without pain hyperkeratosis) with pain, limiting hyperkeratosis) with pain, limiting instrumental ADLa self-care ADL Abbreviation: ADL, activities of daily living. a Data from the National Cancer Institute.11 Table 2. Comparison of Hand-Foot Syndrome and Hand-Foot-Skin Reaction Variable Hand-Foot Syndrome Hand-Foot-Skin Reaction Frequently implicated drugs Capecitabine, cytarabine, doxorubicin, 5-fluorouracil, Sorafenib, sunitinib (multikinase inhibitors)6 taxanes4 Histopathologic findings Hyperkeratosis, parakeratosis Hyperkeratosis, parakeratosis Spongiosis Well-defined horizontal zone of keratinocyte necrosis Focal vacuolization and pyknosis in basal cell layer and discohesion (distinct from basal vacuolization or Dermis with ectatic blood vessels, mild perivascular scattered pyknotic cells often seen in hand-foot lymphohistiocytic infiltrate4,15,16 syndrome) Dermis with ectatic blood vessels, mild perivascular lymphohistiocytic infiltrate with or without eosinophils in dermis15,17 Clinical appearance Edema, erythema, and scale with or without blisters and Scale with surrounding erythema progressing to erosions4,5 hyperkeratosis with or without blisters and erosions6,18 Distribution Symmetrical and diffuse over the palms, soles, and Localized to pressure-bearing or flexural areas on palms digits4,5 and soles6 Onset 24 h to 10 mo after initiation of therapy2,4 (median,
Load more

Recommended publications
  • SYN-40585 SYNRIBO Digital PI, Pil and IFU 5/2021 V3.Indd
    SYN-40585 CONTRAINDICATIONS HIGHLIGHTS OF PRESCRIBING INFORMATION None. These highlights do not include all the information needed to use SYNRIBO safely and WARNINGS AND PRECAUTIONS effectively. See full prescribing information for SYNRIBO. • Myelosuppression: Severe and fatal thrombocytopenia, neutropenia and anemia. Monitor SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use hematologic parameters frequently (2.3, 5.1). Initial U.S. Approval: 2012 • Bleeding: Severe thrombocytopenia and increased risk of hemorrhage. Fatal cerebral hemorrhage and severe, non-fatal gastrointestinal hemorrhage (5.1, 5.2). INDICATIONS AND USAGE Hyperglycemia: Glucose intolerance and hyperglycemia including hyperosmolar non-ketotic SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated • hyperglycemia (5.3). phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the tyrosine kinase inhibitors (TKI) (1). • potential risk to a fetus and to use an effective method of contraception (5.4, 8.1, 8.3). DOSAGE AND ADMINISTRATION ADVERSE REACTIONS Induction Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • Most common adverse reactions (frequency ≥ 20%): thrombocytopenia, anemia, neutropenia, 14 consecutive days of a 28-day cycle (2.1). diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia, infection, and lymphopenia Maintenance Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • (6.1). 7 consecutive days of a 28-day cycle (2.2). • Dose modifications are needed for toxicity (2.3). To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
    [Show full text]
  • A Phase II Study of Paclitaxel and Capecitabine As a First-Line Combination Chemotherapy for Advanced Gastric Cancer
    British Journal of Cancer (2008) 98, 316 – 322 & 2008 Cancer Research UK All rights reserved 0007 – 0920/08 $30.00 www.bjcancer.com A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer Clinical Studies HJ Kang1, HM Chang1, TW Kim1, M-H Ryu1, H-J Sohn1, JH Yook2,STOh2, BS Kim2, J-S Lee1 and Y-K Kang*,1 1 2 Division of Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea Paclitaxel and capecitabine, which have distinct mechanisms of action and toxicity profiles, have each shown high activity as single agents in gastric cancer. Synergistic interaction between these two drugs was suggested by taxane-induced upregulation of thymidine phosphorylase. We, therefore, evaluated the antitumour activity and toxicities of paclitaxel and capecitabine as first-line therapy in patients with advanced gastric cancer (AGC). Patients with histologically confirmed unresectable or metastatic AGC were treated À2 À2 with capecitabine 825 mg m p.o. twice daily on days 1–14 and paclitaxel 175 mg m i.v. on day 1 every 3 weeks until disease progression or unacceptable toxicities. Between June 2002 and May 2004, 45 patients, of median age 57 years (range ¼ 38–73 years), were treated with the combination of capecitabine and paclitaxel. After a median 6 cycles (range ¼ 1–9 cycles) of chemotherapy, 43 were evaluable for toxicity and response. A total of 2 patients showed complete response and 20 showed partial response making the overall response rate 48.9% (95% CI ¼ 30.3–63.5%).
    [Show full text]
  • A Phase II Study of Capecitabine and Docetaxel Combination Chemotherapy in Patients with Advanced Gastric Cancer
    British Journal of Cancer (2004) 90, 1329 – 1333 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer YH Park*,1, B-Y Ryoo1, S-J Choi1and H-T Kim1 1 Division of Haematology and Oncology, Department of Internal Medicine, Korea Institute of Radiological and Medical Science, Seoul, Korea Clinical Capecitabine and docetaxel have considerable single-agent activity in gastric cancer with distinct mechanisms of action and no overlap of key toxicities. A synergistic interaction between these two drugs is mediated by taxane-induced upregulation of thymidine phosphorylase. We investigated the activity and the feasibility of capecitabine and docetaxel combination chemotherapy in patients with previously untreated advanced gastric cancer (AGC). From September 2001 to March 2003, 42 patients with AGC received À2 À2 21-day cycles of oral capecitabine (1250 mg m twice daily on days 1–14) and docetaxel (75 mg m i.v. on day 1). The patients received a total of 164 cycles of chemotherapy. The median age was 53.5 years (range 33–73 years). The overall response rate in the 38 efficacy-evaluable patients was 60% (95% confidence interval, 45–74%). The median progression-free survival was 5.2 months (range, 1.0–15.5 þ months) and the median overall survival was 10.5 months (range, 2.9–23.7 þ months). The most common grade 3/4 adverse events were hand–foot syndrome (HFS: G3 50%), neutropenia (15%) and leucopenia (12%). Further studies of this combination are clearly warranted, albeit with lower doses of both agents (1000 mg mÀ2 twice daily and 60 mg mÀ2) to reduce the rate of HFS and onycholysis.
    [Show full text]
  • Burkitt Lymphoma
    NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Burkitt Lymphoma (Part 1 of 3) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Induction Therapy—Low Risk Combination Regimens1,a Note: All recommendations are Category 2A unless otherwise indicated. REGIMEN DOSING CODOX-M
    [Show full text]
  • HYDREA Product Monograph
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr HYDREA® Hydroxyurea Capsules, 500 mg USP Antineoplastic Agent Bristol-Myers Squibb Canada Date of Initial Authorization: Montreal, Canada MAR 23, 1979 Date of Revision: AUGUST 10, 2021 Submission Control Number: 250623 HYDREA® (hydroxyurea) Page 1 of 26 RECENT MAJOR LABEL CHANGES 1 Indications 02/2020 7 Warnings and Precautions, Hematologic 08/2021 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ........................................................................................... 22 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 4 4.1 Dosing Considerations ............................................................................................
    [Show full text]
  • Metronomic Chemotherapy
    cancers Review Metronomic Chemotherapy Marina Elena Cazzaniga 1,2,*,†, Nicoletta Cordani 1,† , Serena Capici 2, Viola Cogliati 2, Francesca Riva 3 and Maria Grazia Cerrito 1,* 1 School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza (MB), Italy; [email protected] 2 Phase 1 Research Centre, ASST-Monza (MB), 20900 Monza, Italy; [email protected] (S.C.); [email protected] (V.C.) 3 Unit of Clinic Oncology, ASST-Monza (MB), 20900 Monza, Italy; [email protected] * Correspondence: [email protected] (M.E.C.); [email protected] (M.G.C.); Tel.: +39-0392-339-037 (M.E.C.) † Co-first authors. Simple Summary: The present article reviews the state of the art of metronomic chemotherapy use to treat the principal types of cancers, namely breast, non-small cell lung cancer and colorectal ones, and of the most recent progresses in understanding the underlying mechanisms of action. Areas of novelty, in terms of new regimens, new types of cancer suitable for Metronomic chemotherapy (mCHT) and the overview of current ongoing trials, along with a critical review of them, are also provided. Abstract: Metronomic chemotherapy treatment (mCHT) refers to the chronic administration of low doses chemotherapy that can sustain prolonged, and active plasma levels of drugs, producing favorable tolerability and it is a new promising therapeutic approach in solid and in hematologic tumors. mCHT has not only a direct effect on tumor cells, but also an action on cell microenvironment, Citation: Cazzaniga, M.E.; Cordani, by inhibiting tumor angiogenesis, or promoting immune response and for these reasons can be N.; Capici, S.; Cogliati, V.; Riva, F.; considered a multi-target therapy itself.
    [Show full text]
  • Dosage of Capecitabine and Cyclophosphamide Combination Therapy in Patients with Metastatic Breast Cancer
    ANTICANCER RESEARCH 27: 1009-1014 (2007) Dosage of Capecitabine and Cyclophosphamide Combination Therapy in Patients with Metastatic Breast Cancer SHINJI OHNO1, SHOSHU MITSUYAMA2, KAZUO TAMURA3, REIKI NISHIMURA4, MAKI TANAKA5, YUZO HAMADA6, SHOJI KUROKI7 and THE KYUSHU BREAST CANCER STUDY GROUP 1Department of Breast Oncology, National Kyushu Cancer Center Hospital, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395; 2Department of Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu City, Fukuoka 802-0077; 3First Department of Internal Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0818; 4Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh Kumamoto City, Kumamoto 862-8505; 5Department of Surgery, Social Insurance Kurume Daiichi Hospital, 21 Kushihara-machi, Kurume City, Fukuoka 830-0013; 6Department of Breast Surgery, Hirose Hospital, 1-12-12 Watanabedouri Chuo-ku, Fukuoka 810-0004; 7Department of Surgery and Oncology, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan Abstract. Background: Capecitabine is a highly effective and taxane therapy is distressing for women and can lead patients well-tolerated treatment for metastatic breast cancer (MBC) and to consider stopping therapy (1). Intense nausea associated extends survival when combined with docetaxel. Capecitabine with anthracycline-based therapy also adversely affects and cyclophosphamide are orally administered and have patients' quality of life (2). Therefore a chemotherapy preclinical synergy and non-overlapping toxicities. Patients and regimen that minimises these effects is likely to be attractive Methods: Sixteen pretreated MBC patients received escalating to patients. Another important consideration with taxane- doses of oral capecitabine 628 to 829 mg/m2 twice daily (bid) and anthracycline-based therapies is the need for regular plus oral cyclophosphamide 33 to 50 mg/m2 bid, on days 1 to 14 clinic visits or hospitalisations for intravenous administration every 21 days.
    [Show full text]
  • Benefit of Intermediate-Dose Cytarabine-Containing Induction In
    Letters to the Editor ter RFS and EFS rates and showed a marked tendency to Benefit of intermediate-dose cytarabine-containing improve the OS of patients with CEBPAdm in both uni- induction in molecular subgroups of acute myeloid variate and multivariable analyses, as shown in Online leukemia Supplementary Table S2. Five-year RFS, EFS, and OS rates were 85%, 81%, and 88% in the intermediate-dose com- The outcome of acute myeloid leukemia (AML) is pared with 56%, 56%, and 68% in the conventional- affected by disease characteristics as well as treatment dose group, respectively (Figure 1). In total, 13 of 75 1-3 regimens. In the CALGB8525 trial, patients with core (17%) patients with CEBPAdm AML underwent allo- binding factor (CBF)-positive leukemia benefited from geneic transplantation in CR1, including five of 32 (16%) 4 consolidation with a high dose of cytarabine. More in the conventional-dose group and eight of 43 (19%) in 2 recently, high-dose daunorubicin (60-90 mg/m ) has the intermediate-dose group. To analyze results in the 5,6 become widely used. High-dose daunorubicin confers a absence of any possible contributory effect of transplan- favorable prognosis for patients with NPM1 muta- tation, patients were censored at the time of transplanta- 1,7,8 tions. tion in CR1. Patients with CEBPAdm AML exposed to Higher-dose cytarabine was also introduced into AML intermediate-dose cytarabine achieved an increase in 5- 3,9 induction therapy. Recently, we investigated the role of year RFS, censored at the date of transplantation, from intermediate-dose cytarabine in induction therapy of 56% to 83% (hazard ratio [HR], 0.313; 95% confidence AML and found that the introduction of intermediate- interval [95% CI]: 0.119-0.824; Wald P=0.019) (Online dose cytarabine, combined with daunorubicin and omac- Supplementary Figure S3).
    [Show full text]
  • Capecitabine Induces Rapid, Sustained Response in Two Patients with Extensive Oral Verrucous Carcinoma1
    580 Vol. 9, 580–585, February 2003 Clinical Cancer Research Advances in Brief Capecitabine Induces Rapid, Sustained Response in Two Patients with Extensive Oral Verrucous Carcinoma1 Anastasios Salesiotis, Richie Soong, chemical evaluation of pretreatment biopsies from both pa- Robert B. Diasio, Andra Frost, and tients revealed a high level of expression of thymidine phos- Kevin J. Cullen2 phorylase, a key enzyme in the metabolism of capecitabine. Conclusions: Oral VC is a rare entity with a progressive Lombardi Cancer Center, Georgetown University, Washington DC course over years and limited options in terms of treatment. 20007 [A. S., K. C.], and University of Alabama Cancer Center, Birmingham, Alabama [R. D., R. S., A. F.] Preliminary observations in two elderly patients demon- strate that capecitabine, an oral fluoropyrimidine, is well tolerated and may induce rapid, clinically significant re- Abstract sponse. Although not curative, it may provide a cost-effec- Purpose: Oral verrucous carcinoma (VC) has been tra- tive alternative for elderly patients with a significant im- ditionally treated with surgery or radiation with frequent provement in their quality of life. recurrences and significant morbidity. We describe rapid and dramatic response to oral capecitabine in two patients Introduction with advanced refractory VC. Verrucous carcinomata are rare tumors of the oral cavity, Experimental Design: VC is a rare tumor of the oral representing anywhere from 1 to 10% of all oral squamous cavity. It does not metastasize but over time causes morbid- malignancies (1–5). Although oral presentations are most com- ity and mortality through local invasion. Radiation and mon, VC3 may also be present in the larynx or elsewhere in the surgery have been the main treatment modalities but are aerodigestive tract (6).
    [Show full text]
  • Acute Lymphoblastic Leukemia (ALL) (Part 1 Of
    LEUKEMIA TREATMENT REGIMENS: Acute Lymphoblastic Leukemia (ALL) (Part 1 of 12) Note: The National Comprehensive Cancer Network (NCCN) Guidelines® for Acute Lymphoblastic Leukemia (ALL) should be consulted for the management of patients with lymphoblastic lymphoma. Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. They are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any
    [Show full text]
  • Colorectal Cancer
    Chemotherapy Protocol COLORECTAL CANCER CAPECITABINE-MITOMYCIN Regimen • Colorectal Cancer – Capecitabine-Mitomycin Indication • Second / third line therapy of metastatic/advanced colorectal cancer • WHO performance status 0, 1, 2 Adverse Effects Drug Adverse Effect Capecitabine Palmar-plantar erythrodysesthesia, diarrhoea, mucositis, chest pain Mitomycin Nephrotoxicity, myelosuppression (cumulative) The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Regimen • FBC, LFT’s and U&E’s prior to each cycle • Patients with complete or partial dihydropyrimidine dehydrogenase (DPD) deficiency are at increased risk of severe and fatal toxicity during treatment with capecitabine. All patients should be tested for DPD deficiency before initiation (cycle 1) to minimise the risk of these reactions. Dose Modifications The dose modifications listed are for haematological, liver and renal function only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re- escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Version 1.3 (November 2020) Page 1 of 6 Colorectal – Capecitabine-Mitomycin Please discuss all dose reductions / delays with the relevant consultant before prescribing, if appropriate. The approach may be different depending on the clinical circumstances. The following is a general guide only. Haematological Prior to prescribing the following criteria must be met. Criteria Eligible Level Neutrophil equal to or more than 1.5x10 9/L Platelets equal to or more than 100x10 9/L Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL For haematological toxicity, if the neutrophil count is less than 1.5 10 9/L or the platelet count is less than 100 10 9/L, delay the mitomycin treatment until these levels are achieved.
    [Show full text]
  • Predicted Concentrations of Anticancer Drugs in the Aquatic Environment
    Journal of Hazardous Materials 392 (2020) 122330 Contents lists available at ScienceDirect Journal of Hazardous Materials journal homepage: www.elsevier.com/locate/jhazmat Predicted concentrations of anticancer drugs in the aquatic environment: What should we monitor and where should we treat? T M.B. Cristóvãoa,f, R. Janssensb, A. Yadavc, S. Pandeyd, P. Luisb, B. Van der Bruggene, K.K. Dubeyc, M.K. Mandald, J.G. Crespof, V.J. Pereiraa,g,* a iBET - Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal b Materials and Process Engineering, UCLouvain, Louvain-la-Neuve, Belgium c Bioprocess Engineering Laboratory, Department of Biotechnology, Central University of Haryana, Mahendergarh, 123031, Haryana, India d National Institute of Technology Durgapur, M.G. Avenue, Durgapur, West Bengal, India e KULeuven, Leuven, Belgium f LAQV-REQUIMTE/Department of Chemistry, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal g Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal GRAPHICAL ABSTRACT ARTICLE INFO ABSTRACT Editor: D. Aga Anticancer drugs have been detected in the aquatic environment, they have a potent mechanism of action and Keywords: their consumption is expected to drastically increase in the future. Consequently, it is crucial to routinely Anticancer drugs monitor the occurrence of anticancer drugs and to develop effective treatment options to avoid their release into Consumption pattern the environment. Hospitalized and outpatients Prior to implementing a monitoring program, it is important to define which anticancer drugs are more prone Entry route to be found in the surface waters. In this study the consumption of anticancer drugs in the Lisbon region Predicted environmental concentrations (Portugal), Belgium and Haryana state (India) were used to estimate the concentrations that can be expected in surface waters.
    [Show full text]